Squarepoint Ops LLC Purchases 112,250 Shares of Agios Pharmaceuticals, Inc. $AGIO

Squarepoint Ops LLC boosted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 53.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 321,138 shares of the biopharmaceutical company's stock after buying an additional 112,250 shares during the quarter. Squarepoint Ops LLC owned approximately 0.54% of Agios Pharmaceuticals worth $11,917,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of AGIO. AQR Capital Management LLC lifted its position in Agios Pharmaceuticals by 66.8% during the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company's stock worth $1,498,000 after acquiring an additional 20,625 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Agios Pharmaceuticals by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company's stock worth $1,274,000 after purchasing an additional 2,920 shares during the period. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter worth about $40,000. Goldman Sachs Group Inc. lifted its position in shares of Agios Pharmaceuticals by 16.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company's stock worth $19,299,000 after purchasing an additional 91,482 shares during the last quarter. Finally, Woodline Partners LP bought a new stake in Agios Pharmaceuticals during the 1st quarter valued at approximately $597,000.

Insider Activity

In other news, insider Sarah Gheuens sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the sale, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company's stock.

Agios Pharmaceuticals Stock Up 3.2%

AGIO stock opened at $34.63 on Thursday. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00. The company has a market cap of $2.07 billion, a PE ratio of -4.94 and a beta of 0.60. The business's 50-day simple moving average is $35.42 and its 200 day simple moving average is $31.99.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The firm had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. On average, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.82 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, August 7th. Bank of America increased their price objective on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 7th. HC Wainwright raised their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Truist Financial lowered their price objective on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating on the stock in a research note on Friday, July 31st. Finally, TD Cowen raised shares of Agios Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $41.25.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.